Abstract:Macrophages play significant roles in the immune response to various pathogens and in tissue homeostasis. Macrophages can be activated and differentiated into multiple subtypes depending on the microenvironment, including classically activated (M1) and alternatively activated (M2) macrophages. Tumor‐associated macrophages (TAMs), which generally exhibit an M2‐like phenotype, play a critical role in tumor progression, angiogenesis, actual metastasis and immunosuppression. Triptolide, a diterpenoid isolated from the plant Tripterygium wilfordii Hook. F, exerts a unique bioactive spectrum of anti‐inflammatory and anticancer activities. Our previous studies showed that triptolide selectively inhibited the production of cytokines/chemokines in macrophages. But the effect of triptolide on TAMs remains unknown. The aim of this study was to determine if triptolide has any effect on the activation of TAMs and production of proinflammatory cytokines and other tumor‐promoting mediators. Methods The selective cytotoxic effect of triptolide on macrophages derived from blood monocytes (TAMs model in vitro ), neutrophils, lymphocytes purified from BALB/c mouse and 4T1 mammary carcinoma cells was assessed by CCK‐8 assay. The effects of triptolide on the viability of macrophage polarization were examined by flow cytometry. The azoxymethane/dextran sulfate sodium (AOM/DSS)‐induced colon tumor ICR‐1 mice were used to elucidate the role of macrophage targeting in the antitumor activity of triptolide in vivo . BALB/c mice co‐inoculated with 4T1 cells and M2‐polarized RAW264.7 cells (control or pretreated with triptolide) were used to further examine whether triptolide's inhibitory effect on tumor progression is mediated by the targeting of TAMs. Real‐time PCR, Western blot analysis, immunofluorescence staining and flow cytometry were performed to determine the expression of cell surface markers and cytokine production. Results Macrophages were found more highly susceptible to triptolide than neutrophils, lymphocytes and tumor cells. M2‐polarized macrophages were more susceptible than M0/M1‐polarized macrophages. Triptolide inhibited macrophage differentiation toward the M2 phenotype, which was correlated with the reduction of tumors in AOM/DSS‐treated mice. In addition, triptolide abolished the M2 macrophage‐mediated tumor progression in cancer co‐inoculated Xenograft mouse models. Furthermore, triptolide inhibited the expression of the M2 markers, such as CD206, Arginase 1, CD204, and CD163, and inhibited both in vitro and in vivo the secretion of the anti‐inflammatory cytokines, transforming growth factor β1 (TGFβ1) and interleukin (IL)‐10. Conclusions Our study indicated that triptolide selectively inhibited the functions of M2‐polarized macrophages and TAMs. The inhibitory effect of triptolide on TAMs viability, differentiation, and cytokine production may elucidate the major underlying mechanisms of its antitumor activity. Our findings provide important information for the potential clinical application of triptolide in cancer therapy. Support or Funding Information This work was supported by grants from the National Natural Science Foundation of China (No. 81102887, No. 81320108029, No. 81102887, No.81173651, No. 81274146 and No. 81303301)

Triptonide Inhibits the Pathological Functions of Gastric Cancer-Associated Fibroblasts

Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins

Triptonide inhibits growth and metastasis in HCC by suppressing EGFR/PI3K/AKT signaling

Triptonide Acts As a Novel Antiprostate Cancer Agent Mainly Through Inhibition of Mtor Signaling Pathway

Identification of Triptonide As a Therapeutic Agent for Triple Negative Breast Cancer Treatment.

A novel antitumor mechanism of triptonide in colorectal cancer: inducing ferroptosis via the SLC7A11/GPX4 axis

TFF1 Inhibits Proliferation and Induces Apoptosis of Gastric Cancer Cells in Vitro.

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

The Antigastric Cancer Effect of Triptolide is Associated With H19/NF-κB/FLIP Axis

Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer

Anticancer Properties of Triptolide: Inhibition of Tumor-Associated Macrophages Differentiation and Cytokine Production

Inhibition of FNDC1 suppresses gastric cancer progression by interfering with Gβγ-VEGFR2 complex formation

Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells

Triptonodiol, a Diterpenoid Extracted from Tripterygium wilfordii, Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer

Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer

Triptolide Inhibits Ovarian Cancer Cell Invasion by Repression of Matrix Metalloproteinase 7 and 19 and Upregulation of E-cadherin

Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles

Network Pharmacology‑based Investigation of Potential Targets of Triptonodiol Acting on Non-Small-Cell Lung Cancer

Poria Acid, Triterpenoids Extracted from Poria cocos, Inhibits the Invasion and Metastasis of Gastric Cancer Cells

Inhibitive Effect of Triptolide on Invasiveness of Human Fibrosarcoma Cells by Downregulating Matrix Metalloproteinase—9 Expression

Triacanthine enhances the sensitivity of colorectal cancer cells to 5-fluorouracil by regulating RRM2